UK markets close in 2 hours 24 minutes
  • FTSE 100

    7,495.77
    +6.58 (+0.09%)
     
  • FTSE 250

    18,945.82
    +15.25 (+0.08%)
     
  • AIM

    832.60
    -1.93 (-0.23%)
     
  • GBP/EUR

    1.1607
    -0.0005 (-0.05%)
     
  • GBP/USD

    1.2225
    +0.0020 (+0.17%)
     
  • BTC-GBP

    13,792.15
    -69.49 (-0.50%)
     
  • CMC Crypto 200

    396.68
    -5.35 (-1.33%)
     
  • S&P 500

    3,933.92
    -7.34 (-0.19%)
     
  • DOW

    33,597.92
    +1.58 (+0.00%)
     
  • CRUDE OIL

    74.81
    +2.80 (+3.89%)
     
  • GOLD FUTURES

    1,800.40
    +2.40 (+0.13%)
     
  • NIKKEI 225

    27,574.43
    -111.97 (-0.40%)
     
  • HANG SENG

    19,450.23
    +635.41 (+3.38%)
     
  • DAX

    14,236.89
    -24.30 (-0.17%)
     
  • CAC 40

    6,653.61
    -6.98 (-0.10%)
     

Public companies who hold 49% of Celularity Inc. (NASDAQ:CELU) gained 18%, institutions profited as well

If you want to know who really controls Celularity Inc. (NASDAQ:CELU), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 49% to be precise, is public companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

While public companies were the group that benefitted the most from last week’s US$56m market cap gain, institutions too had a 22% share in those profits.

Let's delve deeper into each type of owner of Celularity, beginning with the chart below.

Check out our latest analysis for Celularity

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Celularity?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Celularity. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Celularity's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Celularity. Genting Berhad is currently the largest shareholder, with 21% of shares outstanding. In comparison, the second and third largest shareholders hold about 14% and 11% of the stock. Furthermore, CEO Robert Hariri is the owner of 5.5% of the company's shares.

Our research also brought to light the fact that roughly 54% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Celularity

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Celularity Inc.. As individuals, the insiders collectively own US$31m worth of the US$366m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 16% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Celularity. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

It seems that Private Companies own 4.9%, of the Celularity stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Public Company Ownership

We can see that public companies hold 49% of the Celularity shares on issue. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Celularity , and understanding them should be part of your investment process.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here